Background. The GnRH agonists are the drugs of choice for therapy of CPP. We report on pituitary and gonadal suppression in girls with CPP treated by triptorelin depot 11.25 mg/3months or triptorelin depot 3.75 mg/28 days. Patients and methods.We studied 25 girls with idiopathic CPP (puberty onset < 8 yr; LH peak after GnRH test > 7 IU/L; negative MR scan). All but 3 girls (India, n=2; Hungary, n=1) were white Italian subjects. The patients were treated by triptorelin depot (IPSEN-Biotech, Milan, Italy) in quarterly (gr. A: n=15) or monthly (gr. B: n=10) formulation. Endocrine data were assessed at 0, 3 and 6 months of therapy. Results. In both groups, peak LH levels (IU/L) significantly decreased (p < 0.005) at 3 (gr. A 0.8 ± 0.4; gr. B 1.0 ± 0.4) and 6 months (gr. A 0.8 ± 0.4; gr. B 1.0 ± 0.3) in comparison with baseline values (gr. A 22.5 ± 16.1; gr. B 24.0 ± 16.7); no difference was found between peak LH values at 3 and 6 months. Baseline LH values (IU/L) also decreased (gr. A: 0 m. 1.9 ± 1.7; 3 m. 0.3 ± 0.2; 6 m. 0.3 ± 0.2; gr. B: 0 m. 2.2 ± 2.1; 3 m. 0.4 ± 0.3; 6 m. 0.4 ± 0.2). No peak LH value above the threshold defining a complete suppression (LH peak £ 1.75 IU/L) was detected in both groups. Basal and peak FSH as well as basal 17b-estradiol concentrations also significantly decreased at 3 months in both groups and stabilized thereafter. No significant differences were recorded among the patients treated by the quarterly or monthly preparation at 3 and 6 months of follow-up. Vaginal bleedings or other side effects were not observed. Conclusions. We found that triptorelin depot 11.25 mg/3 months is able to suppress LH peak into pre-pubertal values in 100% of examined patients at 3 and 6 months of therapy. The "new" triptorelin depot 11.25 mg/3months formulation was effective in suppressing pituitary and gonadal secretion as the "classical" 3.75 mg/28 days preparation, suggesting that the new quarterly formulation can be used from the beginning of GnRH analog treatment in girls with CPP.
S. Bertelloni, M. Cappa, G.Chiumello, A. Cicognani, F. De Luca, C. De Sanctis, et al. (2005). Comparative data on reproductive axis suppression by quarterly or monthly triptorelin depot in girls with central precocious puberty (CPP).
Comparative data on reproductive axis suppression by quarterly or monthly triptorelin depot in girls with central precocious puberty (CPP)
CICOGNANI, ALESSANDRO;
2005
Abstract
Background. The GnRH agonists are the drugs of choice for therapy of CPP. We report on pituitary and gonadal suppression in girls with CPP treated by triptorelin depot 11.25 mg/3months or triptorelin depot 3.75 mg/28 days. Patients and methods.We studied 25 girls with idiopathic CPP (puberty onset < 8 yr; LH peak after GnRH test > 7 IU/L; negative MR scan). All but 3 girls (India, n=2; Hungary, n=1) were white Italian subjects. The patients were treated by triptorelin depot (IPSEN-Biotech, Milan, Italy) in quarterly (gr. A: n=15) or monthly (gr. B: n=10) formulation. Endocrine data were assessed at 0, 3 and 6 months of therapy. Results. In both groups, peak LH levels (IU/L) significantly decreased (p < 0.005) at 3 (gr. A 0.8 ± 0.4; gr. B 1.0 ± 0.4) and 6 months (gr. A 0.8 ± 0.4; gr. B 1.0 ± 0.3) in comparison with baseline values (gr. A 22.5 ± 16.1; gr. B 24.0 ± 16.7); no difference was found between peak LH values at 3 and 6 months. Baseline LH values (IU/L) also decreased (gr. A: 0 m. 1.9 ± 1.7; 3 m. 0.3 ± 0.2; 6 m. 0.3 ± 0.2; gr. B: 0 m. 2.2 ± 2.1; 3 m. 0.4 ± 0.3; 6 m. 0.4 ± 0.2). No peak LH value above the threshold defining a complete suppression (LH peak £ 1.75 IU/L) was detected in both groups. Basal and peak FSH as well as basal 17b-estradiol concentrations also significantly decreased at 3 months in both groups and stabilized thereafter. No significant differences were recorded among the patients treated by the quarterly or monthly preparation at 3 and 6 months of follow-up. Vaginal bleedings or other side effects were not observed. Conclusions. We found that triptorelin depot 11.25 mg/3 months is able to suppress LH peak into pre-pubertal values in 100% of examined patients at 3 and 6 months of therapy. The "new" triptorelin depot 11.25 mg/3months formulation was effective in suppressing pituitary and gonadal secretion as the "classical" 3.75 mg/28 days preparation, suggesting that the new quarterly formulation can be used from the beginning of GnRH analog treatment in girls with CPP.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
